Apalutamide Plus ADT Improves PSA-PFS in High-Risk Biochemically Relapsed Prostate Cancer

Apalutamide plus androgen deprivation therapy improved prostate-specific antigen progression-free survival in castration-sensitive prostate cancer.

Related Keywords

,Apalutamide Plus Androgen Deprivation Therapy ,Castration Sensitive Prostate Cancer ,Presto Trial ,Nct03009981 ,